

# Datasheet: MCA2297PE

Description:	RAT ANTI MOUSE CD106:RPE
Specificity:	CD106
Other names:	VCAM-1
Format:	RPE
Product Type:	Monoclonal Antibody
Clone:	MVCAM A (429)
Isotype:	lgG2a
Quantity:	100 TESTS

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .							
		Yes	No	Not Determined	Suggested Dilution			
	Flow Cytometry	•			Neat - 1/10			
	Where this antibody has not been tested for use in a particular technique this does not							
	necessarily exclude its use in such procedures. Suggested working dilutions are given a a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.							
Target Species	Mouse							
Product Form	Purified IgG conjugated to R. Phycoerythrin (RPE) - Iyophilized							
Reconstitution	Reconstitute with 1.0 ml distilled water							
Max Ex/Em	Fluorophore	Excitation N	lax (nm)	Emission Max (nm)				
	RPE 488nm laser	496		578				
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant							
Buffer Solution	Phosphate buffered saline							
Preservative Stabilisers	0.09% Sodium Azide 1% Bovine Serum / 5% Sucrose	Albumin						

Immunogen	Stromal cell line PA6.
External Database	
Links	UniProt:
	P29533 Related reagents
	Entrez Gene:
	22329 Vcam1 Related reagents
Synonyms	Vcam-1
RRID	AB_566437
Fusion Partners	Spleen cells from immunised Lewis rats were fused with cells of the mouse P3X63Ag8.653 myeloma cell line.
Specificity	<b>Rat anti Mouse CD106 antibody, clone MVCAM A (429)</b> recognizes murine vascular adhesion molecule 1 (VCAM-1), a cell surface glycoprotein that is also known as CD106. CD106 is expressed predominantly on endothelial cells and expression is up-regulated during inflammation. The ligand for CD106 is the alpha 4 subunit (CD49d) of the integrin VLA-4 (CD49d/CD29).
	Rat anti Mouse CD106 antibody, clone MVCAM A (429) is reported to partially block VCAM-1 mediated functions ( <u>Kinashi and Springer 1994</u> ).
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul.
	The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR ( <u>BUF041A/B</u> ).
References	1. Kinashi, T. and Springer, T.A. (1994) Adhesion molecules in hematopoietic cells. <u>Blood</u> <u>Cells. 20:25-44.</u>
	2. Lau,. H.Y. and Bhatia, M. (2007) Effect of CP-96,345 on the expression of adhesion molecules in acute pancreatitis in mice. <u>Am J Physiol Gastrointest Liver Physiol. 292:</u> <u>G1283-92.</u>
	3. Woo, J.M. et al. (2010) Treatment with apolipoprotein A-1 mimetic peptide reduces
	lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. <u>Arthritis</u> <u>Res Ther. 12(3):R93.</u>
	<u>Res Ther. 12(3):R93.</u>
	Res Ther. 12(3):R93. 4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal
	Res Ther. 12(3):R93. 4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. J Immune Based Ther Vaccines. 8: 5.
	<ul> <li><u>Res Ther. 12(3):R93.</u></li> <li>4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. <u>J Immune Based Ther Vaccines. 8: 5.</u></li> <li>5. Winnik S <i>et al.</i> (2011) Dietary α-linolenic acid diminishes experimental atherogenesis</li> </ul>
	<ul> <li><u>Res Ther. 12(3):R93.</u></li> <li>4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. <u>J Immune Based Ther Vaccines. 8: 5.</u></li> <li>5. Winnik S <i>et al.</i> (2011) Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. <u>Eur Heart J. 32 (20): 2573-84.</u></li> <li>6. Hamada, T. <i>et al.</i> (2009) Inducible nitric oxide synthase deficiency impairs matrix</li> </ul>
	<ul> <li><u>Res Ther. 12(3):R93.</u></li> <li>4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. <u>J Immune Based Ther Vaccines. 8: 5.</u></li> <li>5. Winnik S <i>et al.</i> (2011) Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. <u>Eur Heart J. 32 (20): 2573-84.</u></li> <li>6. Hamada, T. <i>et al.</i> (2009) Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic</li> </ul>
	<ul> <li><u>Res Ther. 12(3):R93.</u></li> <li>4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. <u>J Immune Based Ther Vaccines. 8: 5.</u></li> <li>5. Winnik S <i>et al.</i> (2011) Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. <u>Eur Heart J. 32 (20): 2573-84.</u></li> <li>6. Hamada, T. <i>et al.</i> (2009) Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. <u>Am J Pathol. 174: 2265-77.</u></li> </ul>
	<ul> <li><u>Res Ther. 12(3):R93.</u></li> <li>4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. <u>J Immune Based Ther Vaccines. 8: 5.</u></li> <li>5. Winnik S <i>et al.</i> (2011) Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. <u>Eur Heart J. 32 (20): 2573-84.</u></li> <li>6. Hamada, T. <i>et al.</i> (2009) Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. <u>Am J Pathol. 174: 2265-77.</u></li> <li>7. Hamada, T. <i>et al.</i> (2008) Metalloproteinase-9 deficiency protects against hepatic</li> </ul>
	<ul> <li><u>Res Ther. 12(3):R93.</u></li> <li>4. Hall, L.J. <i>et al.</i> (2010) Probing local innate immune responses after mucosal immunisation. <u>J Immune Based Ther Vaccines. 8: 5.</u></li> <li>5. Winnik S <i>et al.</i> (2011) Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. <u>Eur Heart J. 32 (20): 2573-84.</u></li> <li>6. Hamada, T. <i>et al.</i> (2009) Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. <u>Am J Pathol. 174: 2265-77.</u></li> </ul>

	angiogenic/inflammatory responses of human coronary artery endothelial cells. Exp Biol
	<u>Med (Maywood). 236: 692-700.</u> 9. Li, M. <i>et al.</i> (2014) The indoleamine 2,3-dioxygenase pathway controls complement-
	dependent enhancement of chemo-radiation therapy against murine glioblastoma. J
	Immunother Cancer. 2: 21.
	10. Kumpers, P. <i>et al.</i> (2011) The synthetic tie2 agonist peptide vasculotide protects
	against vascular leakage and reduces mortality in murine abdominal sepsis. <u>Crit Care. 15</u>
	(5): R261.
	11. Püntener, U. <i>et al.</i> (2012) Long-term impact of systemic bacterial infection on the
	cerebral vasculature and microglia. <u>J Neuroinflammation. 9: 146.</u>
	12. David, S. <i>et al.</i> (2011) Acute administration of recombinant Angiopoietin-1 ameliorates
	multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine. 55
	<u>(2): 251-9.</u>
	13. Kuriyama, N. et al. (2011) Tenascin-C: a novel mediator of hepatic ischemia and
	reperfusion injury. <u>Hepatology. 54 (6): 2125-36.</u>
	14. Braach, N. et al. (2014) RAGE controls activation and anti-inflammatory signalling of
	protein C. <u>PLoS One. 9 (2): e89422.</u>
Storage	Store at +4°C.
	DO NOT FREEZE
	This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Health And Safety	Material Safety Datasheet documentation #20487 available at:
Information	20487: https://www.bio-rad-antibodies.com/uploads/MSDS/20487.pdf
Regulatory	For research purposes only
Polatad Dradus	

### Related Products

#### **Recommended Negative Controls**

#### RAT IgG2a NEGATIVE CONTROL:RPE (MCA1212PE)

#### **Recommended Useful Reagents**

MOUSE SEROBLOCK FcR (BUF041A) MOUSE SEROBLOCK FcR (BUF041B)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio-ra	d.com	Email: antibody_sales_uk@bio-ra	id.com	Email: antibody_sales_de@bio-rad.com

From March 15, 2021, we will no longer supply printed datasheets with our products. Look out for updates on how to access your digital version at bio-rad-antibodies.com 'M376028:210114' © 2021 Bio-Rad Laboratories Inc | Legal | Imprint